Nippon India Pharma Fund - Dividend - Regular Plan

  • Previous Nav

  • Net Change on 04-08-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Dividend | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Nippon India Pharma Fund-Dividend-Dividend 11.54 17.92 52.94 17.48 8.01 20.60
S&P BSE Health Care 13.99 21.25 48.38 10.30 1.71 14.56
S&P BSE Health Care - TRI 14.18 21.49 49.74 11.11 2.37 14.07
S&P BSE SENSEX - TRI 5.00 19.51 2.64 6.49 7.40 12.52

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Dividend-Dividend Jun 05, 2004 52.94 17.48 8.01 2.07 3,092.66
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN - DIVIDEND Jul 03, 1999 52.54 9.13 2.89 2.43 1,154.42
UTI Healthcare Fund - Regular Plan - Income Option Aug 25, 1999 53.84 12.25 4.40 2.81 480.89

Fund Holdings as on 30-June-2020

  • Aurobindo Pharma Limited

  • Cipla Limited

  • Sun Pharmaceutical Industries Limited

  • Dr. Reddy's Laboratories Limited

  • Lupin Limited

  • Divi's Laboratories Limited

  • Syngene International Limited

  • Fortis Healthcare Limited

  • Sanofi India Limited

  • Thyrocare Technologies Limited

  • Cadila Healthcare Limited

  • Biocon Limited

  • Abbott India Limited

  • Narayana Hrudayalaya Limited

  • Alkem Laboratories Limited

  • Indoco Remedies Limited

  • Triparty Repo

  • Laurus Labs Limited

  • Healthcare Global Enterprises Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Cash Margin - Derivatives

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

View More

Fund Manager

Most Recent Dividend

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • 14/01/2013

  • 16/03/2012

  • 28/02/2011

  • 31/08/2009

  • 24/03/2008

  • 22/02/2007

  • 19/12/2005

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹3,092.66 crore. Nippon India Pharma Fund is benchmarked against S&P BSE Health Care as primary index and S&P BSE Health Care - TRI as primary index and S&P BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended up ₹0.51(0.77%)yesterday to ₹67.1694.

Among its top 3 holdings the fund has exposure to Aurobindo Pharma Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan and Kinjal Desai.

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097